bioRxiv · 10.1101/366534
Next Generation-Targeted Amplicon Sequencing (NG-TAS): An optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
Abstract
Circulating tumour DNA (ctDNA) detection and monitoring has enormous potential clinical utility in oncology. We describe here a fast, flexible and cost-effective method to profile multiple genes simultaneously in low input cell-free DNA (cfDNA): Next Generation-Targeted Amplicon Sequencing (NG-TAS). We designed a panel of 377 amplicons spanning 20 cancer genes and tested the NG-TAS pipeline using cell-free DNA from two hapmap lymphoblastoid cell lines. NG-TAS consistently detected mutations in cfDNA when mutation allele fraction was >1%. We applied NG-TAS to a clinical cohort of metastatic breast cancer patients, demonstrating its potential in monitoring the disease. The computational pipeline is available at: https://github.com/cclab-brca/NGTAS_pipeline.
Source connections
Explore related subjects
Keep this discovery
Gao, M., Callari, M., Beddowes, E., Sammut, S.-J., Grzelak, M., Biggs, H., Jones, L., Boumertit, A., Linn, S. C., Cortes, J., Baird, R., Chin, S.-F., Caldas, C.. 2018-07-15. Next Generation-Targeted Amplicon Sequencing (NG-TAS): An optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. https://doi.org/10.1101/366534
Cite the original work for its findings. Save a collection to share your selection of sources.